Login
Login     |     Register     |     Recover Username/Password

General Investing

Originations, Valuations Critical to Growth in BDCs

July 02, 2012

Originations and valuations are the most critical factors right now to selecting a BDC as an investment option as there is more differentiation between companies that are able to capitalize on any dislocation and those that are stuck in the transitional period, says Mike Turner, a Senior Vice President and Research Analyst at Compass Point Research & Trading, LLC.

“For the industry as a whole, credit quality is something that we watch, and arguably, I don’t believe we have hit the trough quite yet. Strong credit quality is typically a reflection of a healthy economy, which should then translate into origination growth,” he said.

Turner likes MCG Capital Corporation (MCGC) although the company is going through a transitional period as it recovers from some sour investments during the past few years in the capital structure. He says MCGC, going forward, is aiming to recycle out of some of those poor-performing investments and reinvest in senior debt positions.

“It’s really a transitional story where they’ve shrunk their balance sheet and right-sized their cost structure. They’re cleaning it up and getting earnings and the dividend to a stabilized level. The process isn’t complete, but in the low $4 range, the stock seems to price in a worst-case scenario,” Turner said. “So at that price, you’re getting a nice dividend yield to wait and the downside protection of buying it at a big discount to NAV.”


TSWT - Subscribe now!

The Wall Street Transcript is a completely unique resource for investors and business researchers.

Over 20,000 CEO, Equity Analyst and Money Manager Interviews

TWST Newsletter

Weekly email with New In-Depth Interviews

Most Popular Interviews
Opportunities in Hepatitis C and Genomic Technologies
David Ferreiro

Published April 26, 2014 in Biotechnology and Pharmaceuticals

Buy ($75)
Investing in Health Care Innovation
Finny Kuruvilla

"We’re a faith-based and socially responsible investing firm"

Published May 16, 2013 in Investing in Health Care

Buy ($75)
A Health Sciences Fund with a Long-Term Focus
Mark W. Oelschlager

"The fund is about $40 million in assets"

Published May 16, 2013 in Investing in Health Care

Buy ($75)
High-Yield Canadian Power Companies
John McIlveen

Published May 14, 2013 in High-Yield Equity Securities

Buy ($75)
Most Popular Reports
Investing in Health Care

Published May 16, 2013

Topics Covered: Health Care - Electronic Health Record Adoption - Biotechnology and Pharmaceutical Investing - Biotechnology and Pharmaceuticals - Biotechnology and Pharmaceutical Companies Valuation - Platform Interoperability and Data Analytics - HITECH Act Incentives - Affordable Care Act
Buy ($175)
Internet Services

Published May 10, 2013

Topics Covered: Increased Mobile Content Traffic - Chinese Online Monetization Trends - Internet Infrastructure and Services Consolidation - Social Networking Economics -
Buy ($175)
Investing Strategies

Published May 10, 2013

Topics Covered: Investing in Financial Services - Long-Term Investing - Large Cap Investing - Value Investing - High Quality Companies - Bottom-up Investing - All-Cap Growth Investing - Investing in Emerging Markets
Buy ($175)
Top Company Interviews
TWST
Register for a Free Account to gain greater access to The Wall Street Transcript right now